Tolerance in liver transplantation: Biomarkers and clinical relevance

World Journal of Gastroenterology

Volumn 22, Issue 34, 2016, Pages 7676-7691

  Baroja Mazo, Alberto ^a   Revilla Nuin, Beatriz ^a   Parrilla, Pascual ^a,b   Martínez Alarcón, Laura ^a   Ramírez, Pablo ^a,b   Pons, José Antonio ^a,b  

^a Murcia Biomedical Research Institute (IMIB)   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Biomarkers; Dendritic cells; Liver transplantation; Operational tolerance; Regulatory T cells

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; MICRORNA; MICRORNA 142 5P; MICRORNA 181A; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; TUMOR MARKER;

B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG WITHDRAWAL; GAMMA DELTA T LYMPHOCYTE; GRAFT RECIPIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOCYTE FUNCTION; MACROPHAGE; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NONHUMAN; PATIENT IDENTIFICATION; REGULATORY T LYMPHOCYTE; REVIEW; TRANSPLANTATION TOLERANCE; ANIMAL; CYTOLOGY; HOMEOSTASIS; IMMUNOLOGY; LIVER FAILURE; METABOLISM;

ANIMALS; BIOMARKERS; BIOMARKERS, TUMOR; DENDRITIC CELLS; HOMEOSTASIS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LIVER FAILURE; LIVER TRANSPLANTATION; MACROPHAGES; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 84988556997     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i34.7676     Document Type: Review

References (163)

1. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603-606 [PMID: 13099277]
2. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926-933 [PMID: 9537430 DOI: 10.1002/hep.510270406]
3. Mazariegos GV, Ramos H, Shapiro R, Zeevi A, Fung JJ, Starzl TE. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transplant Proc 1995; 27: 207-209 [PMID: 7878974]
4. Calne RY. Prope tolerance: the future of organ transplantation-from the laboratory to the clinic. Transplantation 2004; 77: 930-932 [PMID: 15077040]
5. Wieërs G, Gras J, Bourdeaux C, Truong DQ, Latinne D, Reding R. Monitoring tolerance after human liver transplantation. Transpl Immunol 2007; 17: 83-93 [PMID: 17306738 DOI: 10.1016/j.trim.2006.09.020]
6. Adams DH, Sanchez-Fueyo A,Samuel D. From immunosuppression to tolerance. Journal of Hepatology 2015; 62: S170-S185
7. Nepom GT, St Clair EW, Turka LA. Challenges in the pursuit of immune tolerance. Immunol Rev 2011; 241: 49-62 [PMID: 21488889 DOI: 10.1111/j.1600-065X.2011.01003.x]
8. Waldmann H. Tolerance: an overview and perspectives. Nat Rev Nephrol 2010; 6: 569-576 [PMID: 20717099 DOI: 10.1038/nrneph.2010.108]
9. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-779 [PMID: 11560993]
10. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786 [PMID: 11571437]
11. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renaltransplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332-1340 [PMID: 15548972]
12. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970; 18: 723-737 [PMID: 4911896]
13. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164 [PMID: 7636184]
14. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336 [PMID: 12612578 DOI: 10.1038/ni904]
15. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061 [PMID: 12522256 DOI: 10.1126/science.1079490]
16. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337-342 [PMID: 12612581 DOI: 10.1038/ni909]
17. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73 [PMID: 11138001 DOI: 10.1038/83784]
18. Haque R, Lei F, Xiong X, Song J. The regulation of FoxP3-expressing regulatory T cells. Endocr Metab Immune Disord Drug Targets 2011; 11: 334-346 [PMID: 21696363]
19. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25-cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004; 172: 5213-5221 [PMID: 15100259 DOI: 10.4049/jimmunol.172.9.5213]
20. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38 [PMID: 17298177 DOI: 10.1371/journal.pbio.0050038]
21. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, Türbachova I, Hamann A, Olek S, Huehn J. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 2378-2389 [PMID: 17694575 DOI: 10.1002/eji.200737594]
22. Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, Baron U, Stauch D, Kotsch K, Pratschke J, Hamann A, Loddenkemper C, Stein H, Volk HD, Hoffmüller U, Grützkau A, Mustea A, Huehn J, Scheibenbogen C, Olek S. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69: 599-608 [PMID: 19147574 DOI: 10.1158/0008-5472. CAN-08-2361]
23. Issa F, Wood KJ. CD4+ regulatory T cells in solid organ transplantation. Curr Opin Organ Transplant 2010; 15: 757-764 [PMID: 20881492 DOI: 10.1097/MOT.0b013e32834017ae]
24. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009; 114: 3727-3735 [PMID: 19641188 DOI: 10.1182/blood-2009-05-219584]
25. Juvet SC, Whatcott AG, Bushell AR, Wood KJ. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am J Transplant 2014; 14: 750-763 [PMID: 24592900 DOI: 10.1111/ajt.12647]
26. Strom TB, Koulmanda M. Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 2009; 20: 1677-1680 [PMID: 19648467 DOI: 10.1681/ASN.2008101027]
27. Hammerich L, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol 2011; 2011: 345803 [PMID: 21197451 DOI: 10.1155/2011/345803]
28. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, Kuchroo VK, Oukka M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008; 105: 18460-18465 [PMID: 19015529 DOI: 10.1073/pnas.0809850105]
29. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009; 9: 883-889 [PMID: 19935807 DOI: 10.1038/nri2660]
30. Mitchell P, Afzali B, Lombardi G, Lechler RI. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 326-331 [PMID: 19448538 DOI: 10.1097/MOT.0b013e32832ce88e]
31. Mellor AL, Munn DH. Physiologic control of the functional status of Foxp3+ regulatory T cells. J Immunol 2011; 186: 4535-4540 [PMID: 21464094 DOI: 10.4049/jimmunol.1002937]
32. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJ, O'Shea JJ, Hunter CA. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007; 8: 1363-1371 [PMID: 17994025 DOI: 10.1038/ni1537]
33. Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011; 140: 51-64 [PMID: 21073873 DOI: 10.1053/j.gastro.2010.10.059]
34. Dummer CD, Carpio VN, Gonçalves LF, Manfro RC, Veronese FV. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl Immunol 2012; 26: 1-10 [PMID: 21939765 DOI: 10.1016/j.trim.2011.08.009]
35. Hippen KL, Riley JL, June CH, Blazar BR. Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol 2011; 23: 462-468 [PMID: 21820917 DOI: 10.1016/j.smim.2011.07.008]
36. Ashton-Chess J, Dugast E, Colvin RB, Giral M, Foucher Y, Moreau A, Renaudin K, Braud C, Devys A, Brouard S, Soulillou JP. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009; 20: 1113-1122 [PMID: 19357258 DOI: 10.1681/ASN.2008050450]
37. Bhorade SM, Chen H, Molinero L, Liao C, Garrity ER, Vigneswaran WT, Shilling R, Sperling A, Chong A, Alegre ML. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation 2010; 90: 540-546 [PMID: 20628341 DOI: 10.1097/TP.0b013e3181e8dabe]
38. Braudeau C, Racape M, Giral M, Louis S, Moreau A, Berthelot L, Heslan M, Ashton-Chess J, Soulillou JP, Brouard S. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007; 20: 845-855 [PMID: 17854443 DOI: 10.1111/j.1432-2277.2007.00537.x]
39. Iwase H, Kobayashi T, Kodera Y, Miwa Y, Kuzuya T, Iwasaki K, Haneda M, Katayama A, Takeda A, Morozumi K, Watarai Y, Uchida K, Nakao A. Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation. Transplantation 2011; 91: 191-198 [PMID: 21157405 DOI: 10.1097/TP.0b013e3181ffbab4]
40. Li Y, Zhao X, Cheng D, Haga H, Tsuruyama T, Wood K, Sakaguchi S, Tanaka K, Uemoto S, Koshiba T. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008; 86: 1837-1843 [PMID: 19104431 DOI: 10.1097/TP.0b013e31818febc4]
41. Shan J, Guo Y, Luo L, Lu J, Li C, Zhang C, Huang Y, Feng L, Wu W, Long D, Li S, Li Y. Do CD4+ Foxp3+ Treg cells correlate with transplant outcomes: a systematic review on recipients of solid organ transplantation. Cell Immunol 2011; 270: 5-12 [PMID: 21640985 DOI: 10.1016/j.cellimm.2011.05.006]
42. Martínez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, Benítez C, Pons JA, Parrilla P, Ramírez P, Bruguera M, Rimola A, Sánchez-Fueyo A. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845-2857 [PMID: 18654667 DOI: 10.1172/JCI35342]
43. Martínez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A, Lerut J, Latinne D, Margarit C, Bilbao I, Brouard S, Hernández-Fuentes M, Soulillou JP, Sánchez-Fueyo A. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309-319 [PMID: 17241111 DOI: 10.1111/j.1600-6143.2006.01621.x]
44. Pons JA, Revilla-Nuin B, Baroja-Mazo A, Ramírez P, Martínez-Alarcón L, Sánchez-Bueno F, Robles R, Rios A, Aparicio P, Parrilla P. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008; 86: 1370-1378 [PMID: 19034005 DOI: 10.1097/TP.0b013e318188d3e6]
45. Chai JG, Xue SA, Coe D, Addey C, Bartok I, Scott D, Simpson E, Stauss HJ, Hori S, Sakaguchi S, Dyson J. Regulatory T cells, derived from naïve CD4+CD25-T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 2005; 79: 1310-1316 [PMID: 15912097]
46. Yong Z, Chang L, Mei YX, Yi L. Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl Immunol 2007; 17: 120-129 [PMID: 17306743 DOI: 10.1016/j.trim.2006.09.005]
47. Nadig SN, Wieckiewicz J, Wu DC, Warnecke G, Zhang W, Luo S, Schiopu A, Taggart DP, Wood KJ. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809-813 [PMID: 20473306 DOI: 10.1038/nm.2154]
48. Daniele N, Scerpa MC, Landi F, Caniglia M, Miele MJ, Locatelli F, Isacchi G, Zinno F. T(reg) cells: collection, processing, storage and clinical use. Pathol Res Pract 2011; 207: 209-215 [PMID: 21397410 DOI: 10.1016/j.prp.2011.02.003]
49. McMurchy AN, Bushell A, Levings MK, Wood KJ. Moving to tolerance: clinical application of T regulatory cells. Semin Immunol 2011; 23: 304-313 [PMID: 21620722 DOI: 10.1016/j.smim.2011.04.001]
50. Wood KJ. Regulatory T cells in transplantation. Transplant Proc 2011; 43: 2135-2136 [PMID: 21839214 DOI: 10.1016/j.transproce ed.2011.06.050]
51. Muller YD, Seebach JD, Bühler LH, Pascual M, Golshayan D. Transplantation tolerance: Clinical potential of regulatory T cells. Self Nonself 2011; 2: 26-34 [PMID: 21776332 DOI: 10.4161/self.2.1.15422]
52. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009; 30: 656-665 [PMID: 19464988 DOI: 10.1016/j.immuni.2009.04.006]
53. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14: 592-600 [PMID: 12183158]
54. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F, Cattaneo D, Perico N, Remuzzi G. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007-1018 [PMID: 17287424 DOI: 10.1681/ASN.2006101143]
55. Battaglia M. Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go? Transpl Int 2010; 23: 761-770 [PMID: 20553440 DOI: 10.1111/j.1432-2277.2010.01127. x]
56. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070 [PMID: 20952687 DOI: 10.1182/blood-2010-07-293795]
57. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Del Papa B, Perruccio K, Ruggeri L, Sportoletti P, Rosati E, Marconi P, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF. Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. Best Pract Res Clin Haematol 2011; 24: 459-466 [PMID: 21925099 DOI: 10.1016/j.beha.2011.05.005]
58. Trzonkowski P, Bieniaszewska M, Ju?ci?ska J, Dobyszuk A, Krzystyniak A, Marek N, My?liwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immunol 2009; 133: 22-26 [PMID: 19559653 DOI: 10.1016/j.clim.2009.06.001]
59. Li XC, Turka LA. An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol 2010; 6: 577-583 [PMID: 20683480 DOI: 10.1038/nrneph.2010.101]
60. Wieckiewicz J, Goto R, Wood KJ. T regulatory cells and the control of alloimmunity: from characterisation to clinical application. Curr Opin Immunol 2010; 22: 662-668 [PMID: 20869224 DOI: 10.1016/j.coi.2010.08.011]
61. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296 [PMID: 1910679 DOI: 10.1146/annurev.iy.09.040191.001415]
62. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation-friend or foe? Immunity 2001; 14: 357-368 [PMID: 11336681]
63. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990; 171: 307-314 [PMID: 2404081]
64. Auchincloss H, Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH. The role of indirect recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 1993; 90: 3373-3377 [PMID: 8475083]
65. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23: 445-449 [PMID: 12200066]
66. Matzinger P, Guerder S. Does T-cell tolerance require a dedicated antigen-presenting cell? Nature 1989; 338: 74-76 [PMID: 2783992 DOI: 10.1038/338074a0]
67. Zöller M. Intrathymic presentation by dendritic cells and macrophages: their role in selecting T cells with specificity for internal and external nominal antigen. Immunology 1991; 74: 407-413 [PMID: 1722772]
68. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426 [PMID: 17898760 DOI: 10.1038/nature06175]
69. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711 [PMID: 12615891 DOI: 10.1146/annurev.immunol.21.120601.141040]
70. Coates PT, Thomson AW. Dendritic cells, tolerance induction and transplant outcome. Am J Transplant 2002; 2: 299-307 [PMID: 12118850]
71. van Nierop K, de Groot C. Human follicular dendritic cells: function, origin and development. Semin Immunol 2002; 14: 251-257 [PMID: 12163300]
72. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22: 633-642 [PMID: 15894280 DOI: 10.1016/j.immuni.2005.03.013]
73. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113: 6102-6111 [PMID: 19366986 DOI: 10.1182/blood-2008-12-195354]
74. Lu L, Bonham CA, Liang X, Chen Z, Li W, Wang L, Watkins SC, Nalesnik MA, Schlissel MS, Demestris AJ, Fung JJ, Qian S. Liverderived DEC205+B220+CD19-dendritic cells regulate T cell responses. J Immunol 2001; 166: 7042-7052 [PMID: 11390448]
75. Lu L, Woo J, Rao AS, Li Y, Watkins SC, Qian S, Starzl TE, Demetris AJ, Thomson AW. Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med 1994; 179: 1823-1834 [PMID: 8195710]
76. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 2003; 198: 305-313 [PMID: 12874263 DOI: 10.1084/jem.20030323]
77. Waskow C, Liu K, Darrasse-Jèze G, Guermonprez P, Ginhoux F, Merad M, Shengelia T, Yao K, Nussenzweig M. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008; 9: 676-683 [PMID: 18469816 DOI: 10.1038/ni.1615]
78. Young JW, Szabolcs P, Moore MA. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1995; 182: 1111-1119 [PMID: 7561684]
79. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16 [PMID: 9039784]
80. Lu L, Li W, Zhong C, Qian S, Fung JJ, Thomson AW, Starzl TE. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation 1999; 68: 747-757 [PMID: 10515374]
81. Süss G, Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996; 183: 1789-1796 [PMID: 8666935]
82. Tuettenberg A, Huter E, Hubo M, Horn J, Knop J, Grimbacher B, Kroczek RA, Stoll S, Jonuleit H. The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells. J Immunol 2009; 182: 3349-3356 [PMID: 19265111 DOI: 10.4049/jimmunol.0802733]
83. Witsch EJ, Peiser M, Hutloff A, Büchner K, Dorner BG, Jonuleit H, Mages HW, Kroczek RA. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol 2002; 32: 2680-2686 [PMID: 12207353 DOI: 10.1002/1521-4141(200209)32]
84. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490 [PMID: 10753825]
85. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-1222 [PMID: 11067871]
86. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176: 6752-6761 [PMID: 16709834]
87. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 2570-2582 [PMID: 17710230 DOI: 10.1172/JCI31911]
88. Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J, Huang X, Garcia B, White D, Dutartre P, Jevnikar AM, Zhong R. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003; 170: 1304-1312 [PMID: 12538690 DOI: 10.4049/jimmunol.170.3.1304]
89. Schwartz RH, Mueller DL, Jenkins MK, Quill H. T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 1989; 54 Pt 2: 605-610 [PMID: 2534840]
90. Lechmann M, Krooshoop DJ, Dudziak D, Kremmer E, Kuhnt C, Figdor CG, Schuler G, Steinkasserer A. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med 2001; 194: 1813-1821 [PMID: 11748282]
91. Lu L, McCaslin D, Starzl TE, Thomson AW. Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation 1995; 60: 1539-1545 [PMID: 8545887]
92. Lutz MB, Kukutsch NA, Menges M, Rössner S, Schuler G. Culture of bone marrow cells in GM-CSF plus high doses of lipopolysaccharide generates exclusively immature dendritic cells which induce alloantigen-specific CD4 T cell anergy in vitro. Eur J Immunol 2000; 30: 1048-1052 [PMID: 10760792 DOI: 10.1002/(SI CI)1521-4141(200004)30:4<1048::AID-IMMU1048>3.0.CO;2-W]
93. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266 [PMID: 12538684]
94. Selenko-Gebauer N, Majdic O, Szekeres A, Höfler G, Guthann E, Korthäuer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, Knapp W, Stöckl J. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003; 170: 3637-3644 [PMID: 12646628 DOI: 10.4049/jimmunol.170.7.3637]
95. Bonham CA, Peng L, Liang X, Chen Z, Wang L, Ma L, Hackstein H, Robbins PD, Thomson AW, Fung JJ, Qian S, Lu L. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002; 169: 3382-3391 [PMID: 12218160]
96. Chauveau C, Rémy S, Royer PJ, Hill M, Tanguy-Royer S, Hubert FX, Tesson L, Brion R, Beriou G, Gregoire M, Josien R, Cuturi MC, Anegon I. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005; 106: 1694-1702 [PMID: 15920011 DOI: 10.1182/blood-2005-02-0494]
97. Morse D, Choi AM. Heme oxygenase-1: the emerging molecule has arrived. Am J Respir Cell Mol Biol 2002; 27: 8-16 [PMID: 12091240 DOI: 10.1165/ajrcmb.27.1.4862]
98. Lan YY, Wang Z, Raimondi G, Wu W, Colvin BL, de Creus A, Thomson AW. Alternatively activated dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol 2006; 177: 5868-5877 [PMID: 17056511]
99. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigenspecific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018-7031 [PMID: 17513751]
100. Gorczynski RM, Bransom J, Cattral M, Huang X, Lei J, Xiaorong L, Min WP, Wan Y, Gauldie J. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFbeta and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. Clin Immunol 2000; 95: 182-189 [PMID: 10866124 DOI: 10.1006/clim.2000.4860]
101. Tiao MM, Lu L, Tao R, Wang L, Fung JJ, Qian S. Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity. Ann Surg 2005; 241: 497-505 [PMID: 15729074]
102. Chen LC, Delgado JC, Jensen PE, Chen X. Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol 2009; 183: 4094-4102 [PMID: 19684083 DOI: 10.4049/jimmunol.0901081]
103. Reichardt P, Dornbach B, Rong S, Beissert S, Gueler F, Loser K, Gunzer M. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007; 110: 1519-1529 [PMID: 17392507 DOI: 10.1182/blood-2006-10-053793]
104. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006; 176: 705-710 [PMID: 16393950]
105. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI. Development of a crossplatform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861 [PMID: 20501943 DOI: 10.1172/JCI39922]
106. Li XC. The significance of non-T-cell pathways in graft rejection: implications for transplant tolerance. Transplantation 2010; 90: 1043-1047 [PMID: 20686444 DOI: 10.1097/TP.0b013e3181efcfe9]
107. Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S, Inoue S, Blank C, Knechtle SJ, Schlitt HJ, Fändrich F, Geissler EK. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008; 180: 335-349 [PMID: 18097035]
108. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 2006; 203: 1851-1858 [PMID: 16864660 DOI: 10.1084/jem.20060603]
109. Deniz G, Erten G, Kücüksezer UC, Kocacik D, Karagiannidis C, Aktas E, Akdis CA, Akdis M. Regulatory NK cells suppress antigen-specific T cell responses. J Immunol 2008; 180: 850-857 [PMID: 18178824]
110. Kroemer A, Edtinger K, Li XC. The innate natural killer cells in transplant rejection and tolerance induction. Curr Opin Organ Transplant 2008; 13: 339-343 [PMID: 18685327 DOI: 10.1097/MOT.0b013e3283061115]
111. Knops N, Levtchenko E, van den Heuvel B, Kuypers D. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. Int J Pharm 2013; 452: 14-35 [PMID: 23711732 DOI: 10.1016/j.ijpharm.2013.05.033]
112. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940 [PMID: 12954741 DOI: 10.1056/NEJMoa021744]
113. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246: 339-346 [PMID: 10399863]
114. Tjon AS, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, Hansen BE, van der Laan LJ, Tha-In T, Metselaar HJ. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010; 16: 837-846 [PMID: 20583092 DOI: 10.1002/lt.22064]
115. Subramanian S, Trence DL. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 2007; 36: 891-905; vii [PMID: 17983927 DOI: 10.1016/j.ecl.2007.07.003]
116. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14: 1648-1654 [PMID: 18975273 DOI: 10.1002/lt.21588]
117. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011; 17 Suppl 3: S1-S9 [PMID: 21850697 DOI: 10.1002/lt.22410]
118. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293 [PMID: 22500797 DOI: 10.1016/j.cell.2012.03.017]
119. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007; 19: 162-172 [PMID: 17383196 DOI: 10.1016/j.smim.2007.02.008]
120. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162: 2775-2784 [PMID: 10072524]
121. Allen A, Zheng Y, Gardner L, Safford M, Horton MR, Powell JD. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 2004; 172: 4797-4803 [PMID: 15067056 DOI: 10.4049/jimmunol.172.8.4797]
122. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-1087 [PMID: 12130531]
123. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228-236 [PMID: 15643982 DOI: 10.1046/j.1600-6143.2004.00673.x]
124. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351-358 [PMID: 11773639 DOI: 10.1073/pnas.231606698]
125. Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell JC, Thompson CB, Burchill MA, Farrar MA, Turka LA. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004; 172: 5287-5296 [PMID: 15100267]
126. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009; 4: e5994 [PMID: 19543393 DOI: 10.1371/journal.pone.0005994]
127. Akimova T, Kamath BM, Goebel JW, Meyers KE, Rand EB, Hawkins A, Levine MH, Bucuvalas JC, Hancock WW. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant 2012; 12: 3449-3461 [PMID: 22994804 DOI: 10.1111/j.1600-6143.2012.04269.x]
128. Roat E, De Biasi S, Bertoncelli L, Rompianesi G, Nasi M, Gibellini L, Pinti M, Del Giovane C, Zanella A, Di Benedetto F, Gerunda GE, Cossarizza A. Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry. Cytometry A 2012; 81: 303-311 [PMID: 22311717 DOI: 10.1002/cytoa.22019]
129. Wang GY, Yang Y, Li H, Zhang J, Li MR, Zhang Q, Chen GH. Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4(+) CD25(+) Foxp3(+) regulatory T cell expansion. Hepatol Res 2012; 42: 192-202 [PMID: 22103959 DOI: 10.1111/j.1872-034X.2011.00909. x]
130. Wang X, Wang W, Xu J, Hong J, Le Q. Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4(+)CD25(+)Foxp3(+) regulatory T cells. Exp Clin Transplant 2013; 11: 56-62 [PMID: 22769982 DOI: 10.6002/ect.2012.0025]
131. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112 [PMID: 19543266 DOI: 10.1038/nature08155]
132. Whitehouse GP, Sanchez-Fueyo A. Immunosuppression withdrawal following liver transplantation. Clin Res Hepatol Gastroenterol 2014; 38: 676-680 [PMID: 25281267 DOI: 10.1016/j.clinre.2014.06.011]
133. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, Ueda M, Mori T, Kawamoto H, Tanaka Y, Sakaguchi S, Minato N, Wood KJ, Tanaka K. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118-2125 [PMID: 15575917 DOI: 10.1111/j.1600-6143.2004.00611.x]
134. Mazariegos GV, Zahorchak AF, Reyes J, Ostrowski L, Flynn B, Zeevi A, Thomson AW. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003; 3: 689-696 [PMID: 12780560]
135. Jiang S, Lechler RI. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant 2003; 3: 516-524 [PMID: 12752307]
136. Taubert R, Danger R, Londoño MC, Christakoudi S, Martinez-Picola M, Rimola A, Manns MP, Sánchez-Fueyo A, Jaeckel E. Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated. Am J Transplant 2016; 16: 1285-1293 [PMID: 26603835 DOI: 10.1111/ajt.13617]
137. Chesneau M, Michel L, Dugast E, Chenouard A, Baron D, Pallier A, Durand J, Braza F, Guerif P, Laplaud DA, Soulillou JP, Giral M, Degauque N, Chiffoleau E, Brouard S. Tolerant Kidney Transplant Patients Produce B Cells with Regulatory Properties. J Am Soc Nephrol 2015; 26: 2588-2598 [PMID: 25644114 DOI: 10.1681/ASN.2014040404]
138. Newell KA, Asare A, Sanz I, Wei C, Rosenberg A, Gao Z, Kanaparthi S, Asare S, Lim N, Stahly M, Howell M, Knechtle S, Kirk A, Marks WH, Kawai T, Spitzer T, Tolkoff-Rubin N, Sykes M, Sachs DH, Cosimi AB, Burlingham WJ, Phippard D, Turka LA. Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients. Am J Transplant 2015; 15: 2908-2920 [PMID: 26461968 DOI: 10.1111/ajt.13480]
139. Mastoridis S, Martínez-Llordella M, Sanchez-Fueyo A. Biomarkers and immunopathology of tolerance. Curr Opin Organ Transplant 2016; 21: 81-87 [PMID: 26709578 DOI: 10.1097/MOT.0000000000000269]
140. Bohne F, Martínez-Llordella M, Lozano JJ, Miquel R, Benítez C, Londoño MC, Manzia TM, Angelico R, Swinkels DW, Tjalsma H, López M, Abraldes JG, Bonaccorsi-Riani E, Jaeckel E, Taubert R, Pirenne J, Rimola A, Tisone G, Sánchez-Fueyo A. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122: 368-382 [PMID: 22156196 DOI: 10.1172/JCI59411]
141. Vitalone MJ, Wei L, Fujiki M, Lau AH, Littau E, Esquivel C, Martinez OM, Krams SM. Liver microRNA Profile of Induced Allograft Tolerance. Transplantation 2016; 100: 781-790 [PMID: 26950716 DOI: 10.1097/TP.0000000000001105]
142. Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M. Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit 2016; 38 Suppl 1: S1-S20 [PMID: 26977997 DOI: 10.1097/FTD.0000000000000287]
143. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, Ramos H, Todo S, Tzakis A, Fung JJ. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993; 17: 1127-1152 [PMID: 8514264 DOI: 10.1002/hep.1840170629]
144. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, McMichael J, Fung JJ, Starzl TE. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243-249 [PMID: 9020325]
145. Benítez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, Martínez-Llordella M, López M, Angelico R, Bohne F, Sese P, Daoud F, Larcier P, Roelen DL, Claas F, Whitehouse G, Lerut J, Pirenne J, Rimola A, Tisone G, Sánchez-Fueyo A. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58: 1824-1835 [PMID: 23532679 DOI: 10.1002/hep.26426]
146. Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008; 20: 43-47 [PMID: 18773958 DOI: 10.1016/j.trim.2008.08.007]
147. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, Alonso EM, Philogene MC, Ikle D, Poole KM, Bridges ND, Turka LA, Tchao NK. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293 [PMID: 22253395 DOI: 10.1001/jama.2011.2014]
148. Pons JA, Ramírez P, Revilla-Nuin B, Pascual D, Baroja-Mazo A, Robles R, Sanchez-Bueno F, Martinez L, Parrilla P. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant 2009; 23: 329-336 [PMID: 19210687 DOI: 10.1111/j.1399-0012.2008.00944.x]
149. Yoshitomi M, Koshiba T, Haga H, Li Y, Zhao X, Cheng D, Miyagawa A, Sakashita H, Tsuruyama T, Ohe H, Ueda M, Okamoto S, Egawa H, Wood K, Sakaguchi S, Manabe T, Tanaka K, Uemoto S. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009; 87: 606-614 [PMID: 19307800 DOI: 10.1097/TP.0b013e318195a7cb]
150. Mazariegos GV, Zahorchak AF, Reyes J, Chapman H, Zeevi A, Thomson AW. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005; 5: 314-322 [PMID: 15643991 DOI: 10.1111/j.1600-6143.2004.00672.x]
151. Gupta A, Kumar CA, Ningappa M, Sun Q, Higgs BW, Snyder S, Zeevi A, Thomson AW, Mazariegos GV, Sindhi R. Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. Transplantation 2009; 88: 589-594 [PMID: 19696644 DOI: 10.1097/TP.0b013e3181b11f12]
152. Tokita D, Mazariegos GV, Zahorchak AF, Chien N, Abe M, Raimondi G, Thomson AW. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008; 85: 369-377 [PMID: 18301333 DOI: 10.1097/TP.0b013e3181612ded]
153. Castellaneta A, Mazariegos GV, Nayyar N, Zeevi A, Thomson AW. HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation 2011; 91: 1132-1140 [PMID: 21423069 DOI: 10.1097/TP.0b013e31821414c9]
154. García de la Garza R, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA, Silva L, Iñarrairaegui M, Sangro B, Sola I, Pardo F, Quiroga J, Ignacio Herrero J. Immune monitoring of immunosuppression withdrawal of liver transplant recipients. Transpl Immunol 2015; 33: 110-116 [PMID: 26225458 DOI: 10.1016/j.trim.2015.07.006]
155. Ashokkumar C, Talukdar A, Sun Q, Higgs BW, Janosky J, Wilson P, Mazariegos G, Jaffe R, Demetris A, Dobberstein J, Soltys K, Bond G, Thomson AW, Zeevi A, Sindhi R. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009; 9: 179-191 [PMID: 18976293 DOI: 10.1111/j.1600-6143.2008.02459.x]
156. Ba?türk B, Karakayali F, Emiro?lu R, Sözer O, Haberal A, Bal D, Haberal M. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc 2006; 38: 571-574 [PMID: 16549178 DOI: 10.1016/j.transproceed.2005.12.1 08]
157. Zarkhin V, Talisetti A, Li L, Wozniak LJ, McDiarmid SV, Cox K, Esquivel C, Sarwal MM. Expression of soluble HLA-G identifies favorable outcomes in liver transplant recipients. Transplantation 2010; 90: 1000-1005 [PMID: 20814356 DOI: 10.1097/TP.0b013e3181f546af]
158. de la Garza RG, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA, Silva L, Iñarrairaegui M, Sangro B, Sola JJ, Pardo F, Quiroga J, Herrero JI. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl 2013; 19: 937-944 [PMID: 23784747 DOI: 10.1002/lt.23686]
159. Mazariegos GV, Reyes J, Webber SA, Thomson AW, Ostrowski L, Abmed M, Pillage G, Martell J, Awad MR, Zeevi A. Cytokine gene polymorphisms in children successfully withdrawn from immunosuppression after liver transplantation. Transplantation 2002; 73: 1342-1345 [PMID: 11981433]
160. Li L, Wozniak LJ, Rodder S, Heish S, Talisetti A, Wang Q, Esquivel C, Cox K, Chen R, McDiarmid SV, Sarwal MM. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. Am J Transplant 2012; 12: 1218-1228 [PMID: 22300520 DOI: 10.1111/j.1600-6143.2011.03928.x]
161. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, Hayashi M, Kanematsu T, Tanaka K. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449-454 [PMID: 11502975]
162. Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk? Transplantation 2005; 79: 1157-1159 [PMID: 15880061]
163. Tryphonopoulos P, Tzakis AG, Weppler D, Garcia-Morales R, Kato T, Madariaga JR, Levi DM, Nishida S, Moon J, Selvaggi G, Regev A, Nery C, Bejarano P, Khaled A, Kleiner G, Esquenazi V, Miller J, Ruiz P, Ricordi C. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005; 5: 608-613 [PMID: 15707417 DOI: 10.1111/j.1600-6143.2004.00743.x]